DossierENTITY

Legend Biotech

Coverage of Legend Biotech in the Nexus archive.

Earliest in view: Jun 3 · 13:36 UTCMost recent: Jun 3 · 13:36 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 3 · 13:36 UTCSTAT NEWS
STAT+: Legend Biotech emerged as a rare market winner
Legend Biotech's shares surged over 40% following the disclosure of early positive data on its in vivo CAR-T therapy for Non-Hodgkin’s lymphoma, making it a rare market winner amid a broader biotech selloff.